Medical technology software company ContextVision AB (OSE:CONTX) and health informatics company AMRA Medical AB announced on Friday a research partnership to advance diagnostics for metabolic dysfunction-associated steatotic liver disease (MASLD).

The collaboration focuses on developing multimodal imaging biomarkers that integrate artificial intelligence with both ultrasound and magnetic resonance imaging (MRI) technologies.

This partnership expands on ContextVision's Data Quality initiative, which aims to deliver AI-driven, organ-specific imaging solutions for MASLD screening and staging. AMRA Medical contributes its expertise in MRI-based body composition analysis, including liver fat quantification, abdominal fat volume measurement, and muscle assessment.

By combining MRI and ultrasound imaging data, the companies aim to improve diagnostic accuracy, support early detection, and facilitate more personalised treatment strategies for MASLD.

The initiative builds on ContextVision's clinical partnership with the University of Washington and includes additional support from global collaborators such as the University of Waterloo's LITMUS Lab in Canada, who provide ultrasound imaging research, and InPhase Solutions AS in Norway, who provide R&D support.

The effort addresses a pressing global need, as MASLD affects roughly one quarter of the global population and current diagnostic approaches often fall short in identifying the disease during early stages.